Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14 study for CLL patients

 Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14 study for CLL patients

Roche Reports Results of Venclexta/Venclyxto plus Gazyva/Gazyvaro in P-III CLL-14 study for CLL patients

 Shots:

  • The P-III CLL-14 study involves assessing of Venclexta (venetoclax) + Gazyva (obinutuzumab) vs Gazyva + chlorambucil in 432 1L CLL patients
  • The study included 1EP as PFS and 2EP as OR, CR, DOR, OS and demonstrated reduction in risk of disease worsening or death with no new safety signals observed. The study is conducted in collaboration with German CLL Study Group (GCLLSG)
  • Venclexta/Venclyxto is a novel inhibitor of B-cell lymphoma-2 (BCL-2) protein, jointly developed & commercialized by Roche& Abbvie in the US. Gazyva/Gazyvaro is a mAb used to bind CD20 and approved in 90 countries with chlorambucil for CLL

Click here to read full press release/ article | Ref: Roche | Image: China Daily

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post